Alvotech SDB (ALVO-SDB) fair value: what the stock is really worth
As of Nov 19, 2026: fair value (intrinsic value) of Alvotech SDB stock SEK 23.45, price SEK 46.55, that is 49.6% below the price, quality 22 out of 100. Rating: strongly overvalued. Calculated from audited financials with 9 of our 26 valuation models and 37 quality factors, updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Alvotech SDB
ALVO-SDB · STFar too expensive (fair value 50% below the price) and weak company, but rising price: meets 1 of 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 15, 2026.
How to read this chart
18‑month range kr 27.85 – kr 113.00 · fair‑value band kr 16.41 – kr 30.48 · the kr 46.55 price screens above the kr 23.45 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 15, 2026.
Every Wednesday you see whether Alvotech SDB is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer.
Show moreShow less
The company provides AVT02, a high concentration, low-volume adalimumab formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ankylosing spondylitis ulcerative colitis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass.
In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product for the treatment of adult patients with moderate to severe ulcerative colitis and moderate to severely active Crohn's disease; AVT23, a biosimilar to Xolair to treat allergic asthma, chronic spontaneous urticaria (CSU), and nasal polyp; and AVT33, a biosimilar to Keytruda product which is in early phase development.
Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.
Stock analysis
Alvotech SDB (ALVO-SDB) currently trades at kr 46.55, while our model-based Fair Value estimate is kr 23.45, 50% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of kr 36.93 per share, and 0 of the 8 models we run sit above the kr 46.55 price.
Bear case: the Multiples group reads lowest at kr 13.85, and 8 of the 8 models stay below the price. Data coverage for this calculation is low.
Scenario range: kr 16.41 (bear) to kr 30.48 (bull), the price of kr 46.55 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 22/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Alvotech SDB reported revenue of $586M in FY2025 versus $83.0M in FY2022, a compound +91.9%/yr. Reported net income was $27.9M in FY2025.
Key figures
Market cap 16.6B SEK (≈ $1.6B) Small · P/S ratio 32.9 · Net margin −36.3% · Return on assets (EBIT) −17.1% (4-year average) · Operating margin −11.1% · Revenue (TTM) $495M · Revenue growth (YoY) −38.9% · EPS growth (YoY) −99.0%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 13 out of 100 (medium confidence).
What moves the price
The share trades about 24% below its 52-week high and 67% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −50%, ALVO-SDB screens richer than that median.
Fair Value models
All 9 models by family
The fair value above starts from this blend and is adjusted for dilution from new shares.
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Revenue & earnings trend
ALVO-SDB screens overvalued: fair value 50% below the price. Compare with Merck KGaA →
Compare Alvotech SDB with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 608 stocks
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Debt-to-equity by industry
- Price/FCF by industry
- Stock screener with 62 metrics
- Valuation of the Sweden market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Zoetis Inc ZTS | $85.57 | $113.53 | +33% | vs ALVO-SDB |
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥46.88 | ¥52.43 | +12% | vs ALVO-SDB |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,900 | ₹1,983 | +4% | vs ALVO-SDB |
| Haleon plc HLN | $9.08 | $8.47 | −7% | vs ALVO-SDB |
| Merck KGaA MRK | €148.40 | €108.83 | −27% | vs ALVO-SDB |
| Galderma Group GALD | CHF 184.70 | CHF 112.46 | −39% | vs ALVO-SDB |
| Takeda Pharmaceutical Company TAK | $21.27 | $11.23 | −47% | vs ALVO-SDB |
| Sandoz Group SDZ | CHF 81.24 | CHF 41.06 | −49% | vs ALVO-SDB |
| Teva Pharmaceutical Industries Limited TEVA | $42.23 | $20.74 | −51% | vs ALVO-SDB |
| Divi's Laboratories Limited DIVISLAB | ₹11,178 | ₹1,567 | −86% | vs ALVO-SDB |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Alvotech SDB (ALVO-SDB) overvalued or undervalued?
What is the fair value of ALVO-SDB?
What is the quality score of ALVO-SDB?
What is the price target for Alvotech SDB (ALVO-SDB)?
What is the Alvotech SDB stock forecast for 2026?
What is the revenue of Alvotech SDB (ALVO-SDB)?
What is the intrinsic value of Alvotech SDB (ALVO-SDB)?
Is Alvotech SDB stock overvalued or undervalued in 2026?
Is fair value the same as the market price of ALVO-SDB?
How much is Alvotech SDB worth?
What do the bullish and bearish scenarios say about ALVO-SDB?
How solid is the balance sheet of Alvotech SDB (ALVO-SDB)?
How far is ALVO-SDB from its 52-week high?
Which stocks are comparable to Alvotech SDB?
Is Alvotech SDB stock attractive at the current price?
How is the fair value of ALVO-SDB calculated?
Is it still worth investing in stocks now?
What is the share price of Alvotech SDB (ALVO-SDB)?
What should I pay attention to with Alvotech SDB right now?
Key figures of Alvotech SDB
How large is the market capitalisation of Alvotech SDB (ALVO-SDB)?
What is the P/S ratio of Alvotech SDB (ALVO-SDB)?
What is the net margin of Alvotech SDB (ALVO-SDB)?
What is the EBIT return on assets of Alvotech SDB (ALVO-SDB)?
What is the operating margin of Alvotech SDB (ALVO-SDB)?
How fast is revenue growing at Alvotech SDB (ALVO-SDB)?
How fast are earnings growing at Alvotech SDB (ALVO-SDB)?
How much free cash flow does Alvotech SDB (ALVO-SDB) generate?
How much net debt does Alvotech SDB (ALVO-SDB) carry?
Watch Alvotech SDB in the live analysis
One click puts Alvotech SDB on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.